1. Home
  2. ABEO vs GFR Comparison

ABEO vs GFR Comparison

Compare ABEO & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • GFR
  • Stock Information
  • Founded
  • ABEO 1974
  • GFR 2018
  • Country
  • ABEO United States
  • GFR Canada
  • Employees
  • ABEO N/A
  • GFR N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • GFR
  • Sector
  • ABEO Health Care
  • GFR
  • Exchange
  • ABEO Nasdaq
  • GFR Nasdaq
  • Market Cap
  • ABEO 281.0M
  • GFR 330.9M
  • IPO Year
  • ABEO 1980
  • GFR N/A
  • Fundamental
  • Price
  • ABEO $4.36
  • GFR $4.39
  • Analyst Decision
  • ABEO Strong Buy
  • GFR
  • Analyst Count
  • ABEO 5
  • GFR 0
  • Target Price
  • ABEO $18.20
  • GFR N/A
  • AVG Volume (30 Days)
  • ABEO 1.5M
  • GFR 58.8K
  • Earning Date
  • ABEO 11-13-2025
  • GFR 11-03-2025
  • Dividend Yield
  • ABEO N/A
  • GFR N/A
  • EPS Growth
  • ABEO N/A
  • GFR 252.35
  • EPS
  • ABEO 0.99
  • GFR 1.37
  • Revenue
  • ABEO $400,000.00
  • GFR $506,500,154.00
  • Revenue This Year
  • ABEO N/A
  • GFR N/A
  • Revenue Next Year
  • ABEO $324.71
  • GFR $3.61
  • P/E Ratio
  • ABEO $4.41
  • GFR $3.20
  • Revenue Growth
  • ABEO N/A
  • GFR N/A
  • 52 Week Low
  • ABEO $3.93
  • GFR $3.81
  • 52 Week High
  • ABEO $7.54
  • GFR $7.95
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 24.72
  • GFR 40.49
  • Support Level
  • ABEO $5.29
  • GFR $4.67
  • Resistance Level
  • ABEO $5.41
  • GFR $5.10
  • Average True Range (ATR)
  • ABEO 0.24
  • GFR 0.24
  • MACD
  • ABEO -0.08
  • GFR -0.03
  • Stochastic Oscillator
  • ABEO 3.49
  • GFR 7.79

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.

Share on Social Networks: